# Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

> **NCT04630158** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 153 (actual)

## Conditions studied

- Chronic Ocular Pain

## Interventions

- **OTHER:** SAF312 Placebo
- **DRUG:** SAF312

## Key facts

- **NCT ID:** NCT04630158
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-21
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-06-08
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630158, "Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04630158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*